era1 times because of seizures and unrerig/L (normal, < 200 ng/L). Primary adresponsiveness associated with hypoglycenal insufficiency was diagnosed, and mia and hyponatremia. Two brothers therapy with mineralo-and glucocorticoids was initiated. Evaluation of a had died suddenly at the ages of 13 possible autoimmune endocrinopathy inmonths and 13 days, respectively.
A cluded determination of all of the followmaternal grandmother had two brothers ing antibody titers, all of which were who died in early childhood, and a sister undetectable: antiadrenal, antiislet cell, of that grandmother had two sons who antimitochondrial, anti-smooth-muscle, died in early childhood from "hypoantiparietal cell, antithyroglobulin, and natremic dehydration."
antimicrosomal. Seven years later, failAt age 16, when he initially came to ure to develop secondary sex characterisour institution, he was a thin, short boy tics prompted further evaluation. At 15'12 with a eunuchoid body habitus. Physical years of age, his external genitalia examination revealed a scant amount of showed no pubertal changes: there was a pubic hair and minimal scrotal thinning. scant amount of pubic hair, and the Pituitary gonadotropin responses to synphallus and testes were prepubertal in thetic GnRH (2.5 pg/kg) were low [mean size. Bone age was 13 years; serum basal luteinizing hormone (LH) 3.9 IU/L, gonadotropin concentrations were somemaximal increment 2.9 IU/L; and mean what low (FSH 4.2 and LH 1.6 IWL);
basal follicle-stimulating hormone (FSH) serum testosterone was undetectable.
1.9 IU/L, maximal increment 1.6 WL]. The diagnosis of hypogonadotropic hySerum testosterone was 2.1 nmol/L, and pogonadism was suspected, and he was bone age was 13 years. admitted for evaluation of gonadotropin
ENDOCRINE ROUNDS
He was admitted to the Clinical Research Center for detailed evaluation of gonadotropin secretion and responses to pulsatile administration of synthetic GnRH (0.025 pg/kg per dose every 2 h for 5 days). His response to synthetic GnRH was minimal ( Figure 1) An infant boy presented at 2 weeks of age with frequent vomiting, weight loss, dehydration, and apathy. His case history was presented before (Virdis et al. 1983 ) and only a brief summary is outlined here. His brother died suddenly at the age of 2 months; an autopsy revealed interstitial pneumonia, but the adrenal glands were not evaluated. testosterone esters was begun, and secondary sex characteristics developed over the ensuing months.
Discussion
Idiopathic congenital adrenal hypoplasia is a rare disorder with an overall estimated frequency of 1:12,500 live births (Kelch et al. 1984) . Two distinct forms have been identified, based on the histologic appearance of the adrenal glands. The miniature adult form, also called anencephalic or secondary form, is characterized by small adrenal glands with normal architecture. There is a welldefined permanent zone and a greatly reduced fetal zone. This form is believed to be secondary to ACTH deficiency, such as seen in anencephalic infants, infants of mothers who received therapy with glucocorticoids during pregnancy, or infants with congenital anomalies of the hypothalamus or pituitary gland. This secondary form is usually sporadic, although few cases of autosomal recessive inheritance have been reported (Kelch et al. 1984; Prader et al. 1975) ; the observed association of achalasia and adrenal hypoplasia in a subset of familial cases suggests that autosomal recessive congenital adrenal hypoplasia may be heterogeneous (Allgrove et al. 1978 ). The primary, or cytomegalic, form is characterized by an absence of the permanent zone of the adrenal cortex; the cytomegalic cells are larger than normal fetal adrenal cells and have nuclear inclusions due to cytoplasmic invaginations. The primary form of congenital adrenal hypoplasia is an X-linked disorder usually manifesting as adrenal insufficiency early in infancy, with low serum concentrations of glucocorticoids, mineralocorticoids, and androgens. Failure to respond to ACTH stimulation is characteristic. As illustrated by all three case presentations, hypogonadotropic hypogonadism is noted at the expected time of pubertal maturation (Prader et al. 1975; Virdis et al. 1983; Hay et al. 1981; Kelly et al. 1977; Golden et al. 1977; Lippe and Golden 1978; Petersen et al. 1982) .
Clinical signs and symptoms of infants with adrenal hypoplasia include poor feeding, failure to gain weight, hyperpigmentation, vomiting, diarrhea, vascular collapse, and sudden death. Dehydration, hyponatremia, hyperkalemia, acidosis, and hypoglycemia are common biochemical findings characteristic of combined gluco-and mineralocorticoid deficiency. These signs and symptoms are indistinguishable from those seen in male infants with the salt-wasting form of congenital adrenal hyperplasia due to 2 lhydroxylase deficiency. A clue for differentiation between these two possible diagnoses in a male infant is the size of the genitalia. In infants with 21-hydroxylase deficiency, the testicles are normal in size and the phallus may be larger than normal owing to elevated plasma androgen concentrations. In contrast, the testes and phallus are usually small in infants who have adrenal hypoplasia (Kelch et al. 1984) . With prompt diagnosis and replacement therapy, survival has increased greatly (Kelch et al. 1984; Viidis et al. 1983 ). Although the majority of patients present in infancy, some patients similar to case 2 do not present with classic signs and symptoms of adrenal insufficiency until the later childhood years (Hay et al. 198 1, case 2; Kelly et al. 1977; Golden et al. 1977) .
In a male infant, a presumptive diagnosis of congenital adrenal hypoplasia may be reached by determination of serum concentrations of cortisol, aldosterone, 17-hydroxyprogesterone, 17-hydroxypregnenolone, and DHEA and its sulfate, all of which are low. Plasma ACTH concentrations are increased. Demonstration of failure to increase serum concentrations of the abovementioned steroids following administration of ACTH strongly supports the diagnosis (Kelch et al. 1984; Kelly et al. 1977; Petersenet al. 1982) . Distinguishing patients with congenital adrenal hypoplasia from those with hereditary ACTH unresponsiveness, although sometimes difficult, is usually made clinically, as the latter patients do not have significant mineralocorticoid deficiency nor are they gonadotropin deficient (Kelch et al. 1972) .
Replacement therapy with hydrocortisone succinate, fludrocortisone, and salt (NaCl) should be initiated promptly and monitored carefully (Kelch et al. 1984; Hughes 1988) . Careful attention to growth velocity and rate of skeletal maturation is essential since, unlike the 2 1 -hydroxylase-deficiency form of congenital adrenal hyperplasia, there is no useful biochemical marker for adequacy of treatment of patients who have congenital adrenal hypoplasia.
As gonadotropin deficiency is commonly associated with the primary form of adrenal hypoplasia, the patients must be followed closely for physical signs of pubertal maturation (Kelch et al. 1984; Petersen et al. 1982; Zachman et al. 1980) . When a patient with primary adrenal hypoplasia shows no signs of sexual maturation by 13-14 years of age, hypogonadotropic hypogonadism should be suspected. Low serum concentrations of LH, FSH, and testosterone are usually found, and the responses of serum gonadotropin concentrations to a single GnRH bolus are usually low (Dunkel et al. 1985) . A stimulation test with hCG, performed by administration of hCG 2000 U i.m. twice a week for 4-6 weeks, and determination of serum testosterone concentrations before and after the hCG therapy are recommended to evaluate testicular function before therapy with androgens is started (Dunkel et al. 1985) . The majority of reported patients had normal testicular responses to hCG (Kelch et al. 1984; Virdis et al. 1983, case 1; Hay et al. 1981; Kelly et al. 1977; Golden et al. 1977; Lippe and Golden 1978; Petersen et al. 1982; Zachman et al. 1980; Gordon et al. 1984 In an attempt to explain the endocrinologic basis of this disorder, Golden and colleagues (1977) proposed that a prenatal delay in the development of hypothalamic function might lead to the absence of ACTH during the critical period of adrenal development and also to permanent gonadotropin deficiency. There is little evidence to support this theory, however, and it seems unlikely that ACTH deficiency is involved in the pathogenesis as ACTH secretion is normal or increased in patients with primary adrenal hypoplasia. (Petersen et al. 1982 ). This did not differentiate primary pituitary from hypothalamic dysfunction, as most patients who have isolated gonadotropin deficiency, due to GnRH deficiency, as well as patients who have primary pituitary dysfunction, respond poorly or not at all to a single dose of synthetic GnRH (Dunkel et al. 1985) .
To try to differentiate between hypothalamic and pituitary gland dysfunction, more prolonged administration of GnRH is required (Kelch et al. 1984; Barkan et al. 1985) . Several recent reports have suggested pituitary gland dysfunction as the primary defect, based upon lack of gonadotropin responses to prolonged, pulsatile stimulation with synthetic G&I-I (Gordon et al. 1984; Kikuchi et al. 1987; Bovet et al. 1988 ). Gordon and associates (1984) described striking differences in responses to GnRH between a patient with Kallman's syndrome, whose LH and FSH rose to within the normal range after 1 week of therapy, and a patient with congenital adrenal hypoplasia in whom only minimal increases of LH and FSH were found after 16 weeks of therapy. Serum testosterone concentrations increased in the patient with Kallman's syndrome, but not in the patient with adrenal hypoplasia. Similar observations of failure to produce pubertal LH and FSH secretion in patients with X-linked adrenal hypoplasia after prolonged treatment with pulsatile G&I-I have been reported by others (Kikuchi et al. 1987; Bovet et al. 1988) . The possibility of primary pituitary dysfunction is further supported by the finding of Marsden and Zakkhour ( 1978) , who reported cytomegalic changes in the pituitary gland of an infant who died of congenital adrenal hypoplasia.
In contrast, Partsch and Sippell ( 1989) reported successful induction of pubertal concentrations of LH, FSH, and testosterone 2-3 months after initiation of therapy with pulsatile synthetic GnRH, suggesting hypothalamic dysfunction as the principal defect in their patient with congenital X-linked adrenal hypoplasia. At least initially, patients with severe endogenous GnRH deficiency respond to exogenous GnRH with the preferential secretion of FSH (Barkan et al. 1985) . This may be important, as the patients studied by Kikuchi et al. (1987) had increased serum FSH concentrations and normalization of FSH responses to synthetic GnRH although serum LH hyporesponsiveness persisted. Thus, the increases in serum FSH noted in our cases (Figures l-3) , as well as others, support the possibility of a primary hypothalamic abnormality (Kruse et al. 1984) . Finally, in case 2, serum bioactive FSH responses to synthetic GnRH increased after pulsatile GnIU-I therapy similar to findings in patients with idiopathic hypogonadotropic hypogonadism (Padmanabhan et al. 1988 ). Differences in gonadotropin responses of patients with congenital adrenal hypoplasia to the prolonged administration of synthetic GnRH might be attributed to differences in the treatment protocols, but this seems unlikely, since the frequency of pulsatile injections varied only between 90 and 120 min and the dosage range was 0.05-0.2 @kg per dose (Bovet et al. 1988; Gordon et al. 1984; Kikuchi et al. 1987; Kruse et al. 1984; Partsch and Sippelll989) .
Altematively, since histologic or precise genetic confirmation of the diagnosis has been unavailable in patients who have received pulsatile GnRH, the syndrome of congenital adrenal hypoplasia with iso-' lated gonadotropin deficiency may be genetically heterogeneous.
Thus far, no more than one affected individual from an involved family has received prolonged stimulation with synthetic GnRH. It will be important to determine whether G&I-I responsiveness differs among affected boys within a kindred and whether different families have different genetic abnormalities.
Appropriate genetic counseling is an important component of the overall management of families with an affected child. To assist in differentiating between the autosomal recessive and the X-linked forms of congenital adrenal hypoplasia, a detailed pedigree of the proband's family should be obtained, with particular attention to the previous occurrence of neonatal or unexplained deaths, similarly affected individuals within the maternal lineage, and the possibility of consanguinity. Since adrenal insufficiency can precede neurologic symptoms by months to years in individuals with X-linked adrenoleukodystrophy (AID), a distinctly different X-linked disease mapped to Xq28 (Mandel et al. 1989 ) pertinent laboratory assays, such as serum long-chain fatty-acid quantification (elevated in AID), may be indicated to assist in making an accurate diagnosis. In families with a documented affected male infant with X-linked adrenal hypoplasia, the recurrence risk for a subsequent male infant may be as high as SO%, with a similar risk for a female sibling of being a gene carrier. Hammond et al. (1985) suggested that the locus for X-linked congenital adrenal hypoplasia and that for glycerol kinase were located on the short arm of the X chromosome within the region Xpl1.2-p2 1, based on the findings of an interstitial Xp deletion with breakpoints at Xpll.2 and Xp2 1 in a phenotypically normal mother of a male infant who died at 36 h of cytomegalic adrenal hypoplasia with glyceroluria (indicating glycerol kinase deficiency) and omithine transcarbamoyltransferase deficiency. The molecular genetic analyses of multiple unrelated affected males with observed cytologic and submicroscopic interstitial deletions have localized the X-linked congenital adrenal hypoplasia locus to region Xp2 1.3-p2 1.2 (Bartley et al. 1986; Francke et al. 1987; Mandel et al. 1989) between two anonymous DNA sequences, DXS67 and DXS268, with a gene order of Xpter-DSX67-AH-GK-DXS268-DMD-OTC-Xcen (Xp telomere, Xpter; adrenal hypoplasia, AH: glycerol kinase, GK; Duchenne muscular dystrophy, DMD; ornithine transcarbamoyltransferase, OTC; and X centromere, Xcen) (Goonewardena et al. 1989 ). These studies indicate that it may be feasible to use polymorphic DNA markers closely linked to the adrenal hypoplasia locus to provide prenatal diagnostic studies to families with a previously affected member.
Not infrequently, patients with Xlinked adrenal hypoplasia have been found to be affected with additional X-linked diseases such as Duchenne muscular dystrophy, glycerol kinase deficiency, omithine transcarbamoyltransferase deficiency, and mental retardation as a consequence of having an interstitial deletion within Xp2 1 disrupting a number of neighboring, or contiguous, genetic loci (Hammond et al. 1985; Bartley et al. 1986; Francke et al. 1987) . These patients present with a variety of clinical problems depending on which contiguous genes have been disrupted; the various clinical syndromes resulting from different overlapping deletions have been referred to as contiguous deletion syndromes (Schmickell986; Emanuel 1988). Because X-linked adrenal hypoplasia is not uncommonly a consequence of an X-chromosome deletion, affected patients should be evaluated for clinical signs of other diseases mapped to Xp21 and, when appropriate, diagnostic studies, including a karyotype and urine organic acids, should be obtained.
In a male infant from an affected kindred, the finding of normal results of adrenal function at birth does not rule out the possibility of X-linked adrenal hypoplasia, as onset of symptoms may be delayed in some patients (case 1; Hay et al. 1981; Kelly et al. 1977; Golden et al. 1977; Sills et al. 1983) , and thus careful follow-up is indicated.
